Evidence map›Paper›PMID 31620007›Full record

ArticleFrontiers in physiology2019

Renoprotection Provided by Additional Diuretic Treatment in Partially Nephrectomized Ren-2 Transgenic Rats Subjected to the Combined RAS and ET

Ivana Vaněčková, Silvie Hojná, Zdenka Vernerová, Michaela Kadlecová, Hana Rauchová, Elzbieta Kompanowska-Jezierska, Zdeňka Vaňourková, Luděk Červenka, Josef Zicha

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in physiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Ivana VaněčkováDepartment of Experimental Hypertension, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia.
Silvie HojnáDepartment of Experimental Hypertension, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia.
Zdenka VernerováDepartment of Pathology, Third Faculty of Medicine, Charles University, Prague, Czechia.
Michaela KadlecováDepartment of Experimental Hypertension, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia.
Hana RauchováDepartment of Experimental Hypertension, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia.
Elzbieta Kompanowska-JezierskaDepartment of Renal and Body Fluid Physiology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland.
Zdeňka VaňourkováInstitute for Clinical and Experimental Medicine, Prague, Czechia.
Luděk ČervenkaInstitute for Clinical and Experimental Medicine, Prague, Czechia.
Josef ZichaDepartment of Experimental Hypertension, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia.
Czech Academy of Sciences, Institute of Physiology · CZCzech Academy of Sciences · CZInstitute of Clinical and Experimental Medicine · CZCharles University · CZMossakowski Medical Research Institute, Polish Academy of Sciences · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveOur previous study in heterozygous Ren-2 transgenic rats (TGR) demonstrated that long-term treatment with endothelin receptor A (ET DESIGN AND

methodsPartial nephrectomy (NX) was performed at the age of 3 months in TGR rats which were subjected to: (i) RAS blockade alone (angiotensin receptor blocker losartan and angiotensin converting enzyme inhibitor trandolapril), (ii) combined RAS (losartan and trandolapril) and ET

resultsAt the end of the study systolic blood pressure and cardiac hypertrophy were similarly decreased in all treated groups. Survival was significantly improved by ET

conclusionA diuretic added to the combined RAS and ET

Indexed as

atrasentanchronic kidney diseasehydrochlorothiazidelosartannephrectomyrenoprotectiontrandolapril

Identifiers

PMID31620007
PMCPMC6759492
OpenAlexW2969334037

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.